{
    "root": "651f09c7-4bf2-4d89-ae51-0c8ab3c15392",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Bupropion Hydrochloride",
    "value": "20250306",
    "ingredients": [
        {
            "name": "BUPROPION HYDROCHLORIDE",
            "code": "ZG7E5POY8O"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "CROSPOVIDONE (120 .MU.M)",
            "code": "68401960MK"
        },
        {
            "name": "FD&C YELLOW NO. 6 ALUMINUM LAKE",
            "code": "GYP6Z2JR6Q"
        },
        {
            "name": "FUMARIC ACID",
            "code": "88XHZ13131"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE (1600000 WAMW)",
            "code": "RFW2ET671P"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "METHYLCELLULOSE (100 MPA.S)",
            "code": "4GFU244C4J"
        },
        {
            "name": "POLYETHYLENE GLYCOL 8000",
            "code": "Q662QK8M3B"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        }
    ],
    "indications": "bupropion hydrochloride tablets indicated treatment major depressive disorder ( mdd ) , defined diagnostic statistical manual ( dsm ) . efficacy bupropion hydrochloride tablets treatment major depressive episode established two 4-week controlled inpatient trials one 6-week controlled outpatient trial adult subjects mdd [ ( 14 ) ] .",
    "contraindications": "\u2022 starting dose : 200 mg/day given 100 mg twice daily ( 2.1 ) \u2022 general : increase dose gradually reduce seizure risk . ( 2.1 , 5.3 ) \u2022 3 days , may increase dose 300 mg/day , given 100 mg 3 times daily interval least 6 hours doses . ( 2.1 ) \u2022 usual target dose : 300 mg/day 100 mg 3 times daily . ( 2.1 ) \u2022 maximum dose : 450 mg/day given 150 mg 3 times daily . ( 2.1 ) \u2022 periodically reassess dose need maintenance treatment . ( 2.1 ) \u2022 moderate severe hepatic impairment : 75 mg daily . ( 2.2 , 8.7 ) \u2022 mild hepatic impairment : consider reducing dose and/or frequency dosing . ( 2.2 , 8.7 ) \u2022 renal impairment : consider reducing dose and/or frequency . ( 2.3 , 8.6 )",
    "warningsAndPrecautions": "bupropion hydrochloride tablets , usp 75 mg available oral orange , round , unscored , film coated tablets , imprinted `` apo `` one side `` bu `` `` 75 `` side . supplied follows : overbagged 10 film-coated tablets per bag , ndc 55154-4152-0 store 20\u00bac 25\u00bac ( 68\u00baf 77\u00baf ) ; excursions permitted 15\u00bac 30\u00bac ( 59\u00baf 86\u00baf ) [ usp controlled room temperature ] . protect moisture . store tight , light resistant container [ usp ] .",
    "adverseReactions": "\u2022bupropion hydrochloride tablets contraindicated patients seizure disorder . \u2022bupropion hydrochloride tablets contraindicated patients current prior diagnosis bulimia anorexia nervosa higher incidence seizures observed patients treated bupropion hydrochloride tablets [ ( 5.3 ) ] . \u2022bupropion hydrochloride tablets contraindicated patients undergoing abrupt discontinuation alcohol , benzodiazepines , barbiturates , antiepileptic drugs [ ( 5.3 ) , ( 7.3 ) ] . \u2022the maois ( intended treat psychiatric disorders ) concomitantly bupropion hydrochloride tablets within 14 days discontinuing treatment bupropion hydrochloride tablets contraindicated . increased risk hypertensive bupropion hydrochloride tablets used concomitantly maois . bupropion hydrochloride tablets within 14 days discontinuing treatment maoi also contraindicated . starting bupropion hydrochloride tablets patient treated reversible maois linezolid intravenous methylene blue contraindicated [ ( 2.4 , 2.5 ) , ( 5.4 ) , ( 7.6 ) ] . \u2022bupropion hydrochloride tablets contraindicated patients known hypersensitivity bupropion ingredients bupropion hydrochloride tablets . anaphylactoid/anaphylactic stevens-johnson syndrome reported [ ( 5.8 ) ] .",
    "indications_original": "Bupropion hydrochloride tablets are indicated for the treatment of major depressive disorder (MDD), as defined by the Diagnostic and Statistical Manual (DSM). \n                  The efficacy of bupropion hydrochloride tablets in the treatment of a major depressive episode was established in two 4-week controlled inpatient trials and one 6-week controlled outpatient trial of adult subjects with MDD [see Clinical Studies (14)].",
    "contraindications_original": "\u2022 Starting dose: 200 mg/day given as 100 mg twice daily ( 2.1 ) \u2022 General: Increase dose gradually to reduce seizure risk. ( 2.1 , 5.3) \u2022 After 3 days, may increase the dose to 300 mg/day, given as 100 mg 3 times daily at an interval of at least 6 hours between doses. ( 2.1 ) \u2022 Usual target dose: 300 mg/day as 100 mg 3 times daily. ( 2.1 ) \u2022 Maximum dose: 450 mg/day given as 150 mg 3 times daily. ( 2.1 ) \u2022 Periodically reassess the dose and need for maintenance treatment. (2.1 ) \u2022 Moderate to severe hepatic impairment: 75 mg once daily. ( 2.2 , 8.7) \u2022 Mild hepatic impairment: Consider reducing the dose and/or frequency of dosing. ( 2.2 , 8.7 ) \u2022 Renal impairment: Consider reducing the dose and/or frequency. ( 2.3 , 8.6 )",
    "warningsAndPrecautions_original": "Bupropion hydrochloride tablets, USP 75 mg are available for oral administration as orange, round, unscored, film coated tablets, imprinted \"APO\" on one side and \"BU\" over \"75\" on the other side. They are supplied as follows: \n                  Overbagged with 10 film-coated tablets per bag, NDC 55154-4152-0\n                  \n                     Store at 20\u00baC to 25\u00baC (68\u00baF to 77\u00baF); excursions permitted from 15\u00baC to 30\u00baC (59\u00baF to 86\u00baF) [see USP Controlled Room Temperature]. Protect from moisture.\n                  Store in a tight, light resistant container [see USP].",
    "adverseReactions_original": "\u2022Bupropion hydrochloride tablets are contraindicated in patients with a seizure disorder.\n                     \n                        \u2022Bupropion hydrochloride tablets are contraindicated in patients with a current or prior diagnosis of bulimia or anorexia nervosa as a higher incidence of seizures was observed in such patients treated with bupropion hydrochloride tablets [see Warnings and Precautions (5.3)].\n                     \n                        \u2022Bupropion hydrochloride tablets are contraindicated in patients undergoing abrupt discontinuation of alcohol, benzodiazepines, barbiturates, and antiepileptic drugs [see Warnings and Precautions (5.3), Drug Interactions (7.3)].\n                     \n                        \u2022The use of MAOIs (intended to treat psychiatric disorders) concomitantly with bupropion hydrochloride tablets or within 14 days of discontinuing treatment with bupropion hydrochloride tablets are contraindicated. There is an increased risk of hypertensive reactions when bupropion hydrochloride tablets are used concomitantly with MAOIs. The use of bupropion hydrochloride tablets within 14 days of discontinuing treatment with an MAOI is also contraindicated. Starting bupropion hydrochloride tablets in a patient treated with reversible MAOIs such as linezolid or intravenous methylene blue is contraindicated [see Dosage and Administration (2.4, 2.5), Warnings and Precautions (5.4), Drug Interactions (7.6)].\n                     \n                        \u2022Bupropion hydrochloride tablets are contraindicated in patients with known hypersensitivity to bupropion or other ingredients of bupropion hydrochloride tablets. Anaphylactoid/anaphylactic reactions and Stevens-Johnson syndrome have been reported [see Warnings and Precautions (5.8)]."
}